95. 自己免疫性肝炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 58 / 薬物数 : 56 - (DrugBank : 27) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 114
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Abatacept
Stuart Knechtle, M.D.
2020 Phase 1 NCT04203875 United States
ANTI-baffr antibody
Novartis Farmacéutica S.A
2017 Phase 2;Phase 3 EUCTR2017-001555-32-ES Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2;Phase 3 EUCTR2017-001555-32-NL Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-GB Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DK Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-BE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2;Phase 3 EUCTR2017-001555-32-SE Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Azathioprine
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Radboud University Medical Center
2017 Phase 4 NCT02900443 Belgium;Netherlands
University of Sao Paulo General Hospital
2003 Phase 4 NCT02463331 -
Veloxis Pharmaceuticals
2007 Phase 2 NCT00608894 Canada;United States
Azathioprine + prednisolone
Institute of Liver and Biliary Sciences, India
2024 Phase 2/Phase 3 NCT06650124 -
Belimumab
University Health Network, Toronto
2024 Phase 2 NCT06381453 Canada
Budesonid
Umeå University Hospital
2020 Phase 4 EUCTR2018-003381-14-SE Sweden
Budesonide
Dr. Falk Pharma GmbH
2001 Phase 2/Phase 3 NCT00838214 Germany
Mayo Clinic
2007 - NCT00587119 United States
Calcium
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Cannabidiol
Stero Biotechs Ltd.
2019 Phase 2 NCT04129489 Israel
Chloroquine diphosphate
University of Sao Paulo General Hospital
2003 Phase 4 NCT02463331 -
Chloroquine diphosphate 250MG
University of Sao Paulo General Hospital
2002 Phase 4 NCT01980745 Brazil
Collection OF samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Cyclosporin A
West China Hospital
2021 Phase 4 NCT04376528 China
Cyclosporine-A
Tehran University of Medical Sciences
2005 Phase 3 NCT01170351 Iran, Islamic Republic of
Denosumab
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Dietary assignment
Indiana University
2023 - NCT06250309 United States
Efalizumab
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Erythropoietin
Northwestern University
2019 Early Phase 1 NCT03842254 United States
High protein high fiber diet
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2012 - NCT01655121 Mexico
HR19042 capsule
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 1 NCT06922305 China
HR19042 capsules
Jiangsu HengRui Medicine Co., Ltd.
2022 Phase 2 NCT05476900 China
Ianalumab
Novartis Pharma AG
2018 Phase 2;Phase 3 EUCTR2017-001555-32-NL Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-GB Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DK Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-CZ Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-BE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2;Phase 3 EUCTR2017-001555-32-SE Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
IGG IL2/RO7049665
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-003990-23-IT Australia;Canada;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-003990-23-PT Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-NL Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-DE Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
Infliximab
University Medical Centre Hamburg-Eppendorf
2018 Phase 2 EUCTR2017-003311-19-DE Germany
Interleukin 2
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT01988506 France
JKB-122
TaiwanJ Pharmaceuticals Co., Ltd
2020 Phase 2 NCT04371718 -
2016 Phase 2 NCT02556372 United States
JKB-122 IN capsule or tablet form
TaiwanJ Pharmaceuticals Co., Ltd
2020 Phase 1 NCT04313205 -
Methylprednisolone and azathioprine
Xiaoli Fan
2021 Phase 4 NCT04933292 China
Methylprednisolone and mycophenolate mofetil
Xiaoli Fan
2021 Phase 4 NCT04933292 China
Minodronic acid
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Mycophenolate mofeti
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Mycophenolate mofetil
Institute of Liver and Biliary Sciences, India
2024 Phase 2/Phase 3 NCT06650124 -
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Radboud University Medical Center
2017 Phase 4 NCT02900443 Belgium;Netherlands
West China Hospital
2021 Phase 4 NCT04376528 China
Orbcel-C
University of Birmingham
2018 Phase 1/Phase 2 NCT02997878 United Kingdom
Plasma exchange
Institute of Liver and Biliary Sciences, India
2025 - NCT06855667 India
Prednisolon
Umeå University Hospital
2020 Phase 4 EUCTR2018-003381-14-SE Sweden
Prednisolone sodium succinate
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Prednisone
Dr. Falk Pharma GmbH
2001 Phase 2/Phase 3 NCT00838214 Germany
University of Sao Paulo General Hospital
2003 Phase 4 NCT02463331 -
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Regulatory T cells
Nanjing Medical University
2016 Phase 1/Phase 2 NCT02704338 -
Risedronic acid
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
RO7049665
Hoffmann-La Roche
2021 Phase 2 NCT04790916 Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;Portugal;United Kingdom
RO7049665/IGG-IL2/ IGG-IL2nd2
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-003990-23-IT Australia;Canada;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-003990-23-PT Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-NL Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-DE Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
Siplizumab
Elizabeth C. Verna
2024 Phase 1 NCT06455280 United States
Spif
Christopher O'Brien, MD
2014 Phase 1 NCT02239562 United States
Steroid
Institute of Liver and Biliary Sciences, India
2025 - NCT06855667 India
Synthetic preimplantation factor
Christopher O'Brien, MD
2019 Phase 2 NCT03593460 -
Tacrolimus
Hiroshima University Hospital
2019 - JPRN-UMIN000030743 Japan
Veloxis Pharmaceuticals
2007 Phase 2 NCT00608894 Canada;United States
Treatment with azathioprin
Rigshospitalet, Denmark
2005 Phase 4 NCT00687180 Denmark
Treatment with mycophenolat mofetil
Rigshospitalet, Denmark
2005 Phase 4 NCT00687180 Denmark
Ursodeoxycholic acid combination OF immunosuppressive agents
Xiaoli Fan
2016 - NCT02936596 China
Various
Umeå University Hospital
2020 Phase 4 EUCTR2018-003381-14-SE Sweden
VAY736
Novartis Farmacéutica S.A
2017 Phase 2;Phase 3 EUCTR2017-001555-32-ES Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2;Phase 3 EUCTR2017-001555-32-NL Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-GB Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DK Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-CZ Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-BE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2;Phase 3 EUCTR2017-001555-32-SE Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Novartis Pharmaceuticals
2018 Phase 2/Phase 3 NCT03217422 Argentina;Belgium;Canada;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
Vitamin D
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Zetomipzomib IN OPEN-label extension
Kezar Life Sciences, Inc.
2023 Phase 2 NCT05569759 United States
Zoledronic acid
Hyogo college of medicine
2018 - JPRN-UMIN000031353 Japan
Stuart Knechtle, M.D.
2020 Phase 1 NCT04203875 United States
ANTI-baffr antibody
Novartis Farmacéutica S.A
2017 Phase 2;Phase 3 EUCTR2017-001555-32-ES Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2;Phase 3 EUCTR2017-001555-32-NL Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-GB Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DK Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-BE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2;Phase 3 EUCTR2017-001555-32-SE Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Azathioprine
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Radboud University Medical Center
2017 Phase 4 NCT02900443 Belgium;Netherlands
University of Sao Paulo General Hospital
2003 Phase 4 NCT02463331 -
Veloxis Pharmaceuticals
2007 Phase 2 NCT00608894 Canada;United States
Azathioprine + prednisolone
Institute of Liver and Biliary Sciences, India
2024 Phase 2/Phase 3 NCT06650124 -
Belimumab
University Health Network, Toronto
2024 Phase 2 NCT06381453 Canada
Budesonid
Umeå University Hospital
2020 Phase 4 EUCTR2018-003381-14-SE Sweden
Budesonide
Dr. Falk Pharma GmbH
2001 Phase 2/Phase 3 NCT00838214 Germany
Mayo Clinic
2007 - NCT00587119 United States
Calcium
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Cannabidiol
Stero Biotechs Ltd.
2019 Phase 2 NCT04129489 Israel
Chloroquine diphosphate
University of Sao Paulo General Hospital
2003 Phase 4 NCT02463331 -
Chloroquine diphosphate 250MG
University of Sao Paulo General Hospital
2002 Phase 4 NCT01980745 Brazil
Collection OF samples
Institut National de la Santé Et de la Recherche Médicale, France
2021 - NCT04902807 -
Cyclosporin A
West China Hospital
2021 Phase 4 NCT04376528 China
Cyclosporine-A
Tehran University of Medical Sciences
2005 Phase 3 NCT01170351 Iran, Islamic Republic of
Denosumab
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Dietary assignment
Indiana University
2023 - NCT06250309 United States
Efalizumab
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Erythropoietin
Northwestern University
2019 Early Phase 1 NCT03842254 United States
High protein high fiber diet
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2012 - NCT01655121 Mexico
HR19042 capsule
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 1 NCT06922305 China
HR19042 capsules
Jiangsu HengRui Medicine Co., Ltd.
2022 Phase 2 NCT05476900 China
Ianalumab
Novartis Pharma AG
2018 Phase 2;Phase 3 EUCTR2017-001555-32-NL Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-GB Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DK Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-CZ Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-BE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2;Phase 3 EUCTR2017-001555-32-SE Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
IGG IL2/RO7049665
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-003990-23-IT Australia;Canada;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-003990-23-PT Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-NL Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-DE Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
Infliximab
University Medical Centre Hamburg-Eppendorf
2018 Phase 2 EUCTR2017-003311-19-DE Germany
Interleukin 2
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT01988506 France
JKB-122
TaiwanJ Pharmaceuticals Co., Ltd
2020 Phase 2 NCT04371718 -
2016 Phase 2 NCT02556372 United States
JKB-122 IN capsule or tablet form
TaiwanJ Pharmaceuticals Co., Ltd
2020 Phase 1 NCT04313205 -
Methylprednisolone and azathioprine
Xiaoli Fan
2021 Phase 4 NCT04933292 China
Methylprednisolone and mycophenolate mofetil
Xiaoli Fan
2021 Phase 4 NCT04933292 China
Minodronic acid
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Mycophenolate mofeti
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Mycophenolate mofetil
Institute of Liver and Biliary Sciences, India
2024 Phase 2/Phase 3 NCT06650124 -
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Radboud University Medical Center
2017 Phase 4 NCT02900443 Belgium;Netherlands
West China Hospital
2021 Phase 4 NCT04376528 China
Orbcel-C
University of Birmingham
2018 Phase 1/Phase 2 NCT02997878 United Kingdom
Plasma exchange
Institute of Liver and Biliary Sciences, India
2025 - NCT06855667 India
Prednisolon
Umeå University Hospital
2020 Phase 4 EUCTR2018-003381-14-SE Sweden
Prednisolone sodium succinate
Leiden university medical centre
2018 Phase 4 EUCTR2016-001038-91-BE Belgium;Netherlands
2016 Phase 4 EUCTR2016-001038-91-NL Netherlands
Prednisone
Dr. Falk Pharma GmbH
2001 Phase 2/Phase 3 NCT00838214 Germany
University of Sao Paulo General Hospital
2003 Phase 4 NCT02463331 -
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal
2008 Phase 4 EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal
Regulatory T cells
Nanjing Medical University
2016 Phase 1/Phase 2 NCT02704338 -
Risedronic acid
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
RO7049665
Hoffmann-La Roche
2021 Phase 2 NCT04790916 Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;Portugal;United Kingdom
RO7049665/IGG-IL2/ IGG-IL2nd2
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-003990-23-IT Australia;Canada;Germany;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-003990-23-PT Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-NL Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
2021 Phase 2 EUCTR2020-003990-23-DE Australia;Canada;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;United Kingdom
Siplizumab
Elizabeth C. Verna
2024 Phase 1 NCT06455280 United States
Spif
Christopher O'Brien, MD
2014 Phase 1 NCT02239562 United States
Steroid
Institute of Liver and Biliary Sciences, India
2025 - NCT06855667 India
Synthetic preimplantation factor
Christopher O'Brien, MD
2019 Phase 2 NCT03593460 -
Tacrolimus
Hiroshima University Hospital
2019 - JPRN-UMIN000030743 Japan
Veloxis Pharmaceuticals
2007 Phase 2 NCT00608894 Canada;United States
Treatment with azathioprin
Rigshospitalet, Denmark
2005 Phase 4 NCT00687180 Denmark
Treatment with mycophenolat mofetil
Rigshospitalet, Denmark
2005 Phase 4 NCT00687180 Denmark
Ursodeoxycholic acid combination OF immunosuppressive agents
Xiaoli Fan
2016 - NCT02936596 China
Various
Umeå University Hospital
2020 Phase 4 EUCTR2018-003381-14-SE Sweden
VAY736
Novartis Farmacéutica S.A
2017 Phase 2;Phase 3 EUCTR2017-001555-32-ES Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Novartis Pharma AG
2018 Phase 2;Phase 3 EUCTR2017-001555-32-NL Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-GB Argentina;Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DK Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-DE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-CZ Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2018 Phase 2;Phase 3 EUCTR2017-001555-32-BE Argentina;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Japan;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
2017 Phase 2;Phase 3 EUCTR2017-001555-32-SE Belgium;Canada;Czech Republic;Denmark;Germany;Japan;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
Novartis Pharmaceuticals
2018 Phase 2/Phase 3 NCT03217422 Argentina;Belgium;Canada;Czechia;Denmark;Germany;Japan;Netherlands;Singapore;Spain;Sweden;Switzerland;United Kingdom;United States
Vitamin D
Juntendo University School of Medicine
2014 - JPRN-UMIN000013659 Japan
Zetomipzomib IN OPEN-label extension
Kezar Life Sciences, Inc.
2023 Phase 2 NCT05569759 United States
Zoledronic acid
Hyogo college of medicine
2018 - JPRN-UMIN000031353 Japan